Free Trial

Alumis (ALMS) Competitors

Alumis logo
$3.31 -0.09 (-2.65%)
Closing price 04:00 PM Eastern
Extended Trading
$3.29 -0.02 (-0.60%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALMS vs. SION, ANAB, NUVB, TRVI, DAWN, STOK, GHRS, SANA, URGN, and AUTL

Should you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Sionna Therapeutics (SION), AnaptysBio (ANAB), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), Day One Biopharmaceuticals (DAWN), Stoke Therapeutics (STOK), GH Research (GHRS), Sana Biotechnology (SANA), Urogen Pharma (URGN), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry.

Alumis vs. Its Competitors

Alumis (NASDAQ:ALMS) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlumisN/AN/A-$294.23MN/AN/A
Sionna TherapeuticsN/AN/A-$61.69MN/AN/A

In the previous week, Sionna Therapeutics had 5 more articles in the media than Alumis. MarketBeat recorded 5 mentions for Sionna Therapeutics and 0 mentions for Alumis. Sionna Therapeutics' average media sentiment score of 1.15 beat Alumis' score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alumis Neutral
Sionna Therapeutics Positive

Sionna Therapeutics' return on equity of 0.00% beat Alumis' return on equity.

Company Net Margins Return on Equity Return on Assets
AlumisN/A -406.27% -107.29%
Sionna Therapeutics N/A N/A N/A

Alumis presently has a consensus price target of $22.86, suggesting a potential upside of 590.55%. Sionna Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 83.68%. Given Alumis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alumis is more favorable than Sionna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22
Sionna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Sionna Therapeutics beats Alumis on 5 of the 9 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALMS vs. The Competition

MetricAlumisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$184.98M$2.92B$5.53B$9.03B
Dividend YieldN/A2.44%5.24%4.07%
P/E RatioN/A20.3027.1920.03
Price / SalesN/A251.54414.39108.98
Price / CashN/A41.7026.2128.59
Price / Book0.607.397.925.55
Net Income-$294.23M-$55.04M$3.17B$248.49M
7 Day Performance10.33%3.01%2.18%5.37%
1 Month Performance-7.80%-0.21%1.25%6.63%
1 Year PerformanceN/A4.48%33.90%21.20%

Alumis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALMS
Alumis
2.8797 of 5 stars
$3.31
-2.6%
$22.86
+590.5%
N/A$184.98MN/A0.00N/AGap Down
SION
Sionna Therapeutics
N/A$15.05
+1.5%
$38.50
+155.8%
N/A$664.01MN/A0.0035Gap Up
ANAB
AnaptysBio
2.2604 of 5 stars
$22.58
-3.4%
$42.38
+87.7%
-2.8%$663.25M$91.28M-4.65100
NUVB
Nuvation Bio
3.5826 of 5 stars
$1.95
-1.3%
$7.17
+268.5%
-31.2%$661.81M$7.87M-0.8360
TRVI
Trevi Therapeutics
3.2509 of 5 stars
$5.61
-0.9%
$20.29
+261.6%
+128.5%$659.76MN/A-12.5020
DAWN
Day One Biopharmaceuticals
1.6821 of 5 stars
$6.41
-1.2%
$30.57
+377.3%
-50.4%$649.21M$131.16M-9.0260Upcoming Earnings
STOK
Stoke Therapeutics
3.985 of 5 stars
$11.71
-1.1%
$23.20
+98.1%
-12.5%$642.92M$36.56M14.91100
GHRS
GH Research
1.5435 of 5 stars
$12.34
-0.5%
$32.00
+159.3%
+26.9%$641.53MN/A-15.6110Analyst Upgrade
SANA
Sana Biotechnology
2.5452 of 5 stars
$2.83
-1.6%
$8.60
+204.4%
-37.2%$636.98MN/A-3.21380
URGN
Urogen Pharma
4.4473 of 5 stars
$13.38
+2.1%
$32.86
+145.6%
-15.1%$621.10M$90.40M-4.24200Analyst Forecast
AUTL
Autolus Therapeutics
2.1039 of 5 stars
$2.30
-0.6%
$9.32
+306.1%
-31.3%$611.86M$10.12M-2.61330

Related Companies and Tools


This page (NASDAQ:ALMS) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners